Manuscript Title: The Real-World Clinical Benefits of GLP-1 Receptor Agonist Treatment

Author List:

Henriette Coetzer, MD[1]

Caroline Margiotta, MA[1]

Amy Marr, PhD[1]

Razia Hashmi, MD[2]

Jason Kay, PharmD[2]

Vikrant Vats, PhD[2]

Stuart Hagen, PhD[2]

Stephanie Tomlin, MS[1]

Laura Anatale-Tardiff, MPH[1]

David Wennberg, MD[1]

Affiliations: 1) Blue Health Intelligence, Chicago, IL; 2) Blue Cross Blue Shield Association, Chicago, IL

Corresponding Author: Henriette Coetzer, MD, Blue Health Intelligence, 200 E Randolph St, Suite 3050, Chicago, IL 60601

henriette.coetzer@bluehealthintelligence.com

Manuscript word count: 2597, excluding abstract, acknowledgements, and references

Abstract

Background: The cardiovascular, metabolic and renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been established in randomized trials with carefully selected patients. Real-world evidence of GLP-1RA effects on progression to end-stage renal disease (ESRD), end-stage liver disease (ESLD), and major adverse cardiovascular events (MACE) is scant.

Methods: We conducted a large retrospective cohort study of GLP1-RA use in adults using a national medical and pharmacy claims dataset. GLP-1RA users were stratified by diabetes status and propensity score-matched to controls. Outcomes were incident ESRD, ESLD, MACE overall and by treatment persistence (<1 year, 1–<2 years, ≥2 years). Cox models were used to estimate adjusted hazard ratios (HRs) and to calculate confidence intervals (CIs).

Results: In members with diabetes, GLP-1RA therapy was associated with reduced risks of ESRD (HR, 0.55; 95% CI, 0.49 to 0.61), ESLD (HR=0.66; 95% CI 0.60-0.73) and MACE (HR=0.90; 95% CI 0.86-0.93). In members without diabetes, while the incidence rates of adverse outcomes were lower, treatment with GLP-1RAs still resulted in lower risk of ESRD (HR=0.66, CI 0.46-0.94), ESLD (HR-0.76, CI 0.62-0.93) and MACE (HR=0.86, CI 92-0.99). Persistent GLP-1RA treatment (≥2 years) in members with diabetes resulted in the largest observed reduction in ESRD, ESLD, and MACE risk.

Conclusions: GLP-1RA treatment was associated with reduced incidence of kidney and liver failure and MACE. The impact of GLP-1RA treatment was greatest in members with diabetes and those persisting for ≥2 years.

Introduction

Obesity and type-2 diabetes (T2DM) continue to drive rising morbidity, mortality, and healthcare costs in the United States.[1-6] Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control in T2DM, have emerged as transformative therapeutics for multiple indications. [7-11] Randomized controlled trials (RCTs) including LEADER, SUSTAIN-6, and REWIND demonstrated GLP-1RA efficacy in reducing major adverse cardiovascular events (MACE), improving renal outcomes, and contributing to weight loss in patients with and without diabetes.[12] These findings have rapidly expanded the clinical indications and utilization of GLP-1RA therapies.

Preclinical and translational studies find GLP-1RAs exert anti-inflammatory effects, enhance natriuresis and reduce oxidative stress, which improves endothelial function. These mechanisms appear to preferentially benefit microvasculature of the kidneys and brain, with less immediate impact on macrovascular territories such as coronary arteries.[13-17] However, GLP-1RA clinical trials have consistently underrepresented older adults, individuals with advanced chronic kidney disease (CKD), and those with multiple chronic conditions - populations common in real world practice who may experience different risks, adherence challenges, and therapeutic benefits.

We evaluated the real-world association between GLP-1RA treatment and the incidence and timing of end-stage renal disease (ESRD), end-stage liver disease (ESLD), and MACE using a large national claims database in members with and without diabetes. Leveraging real-world data, we aim to extend the understanding of GLP-1RA therapeutic effects beyond the constraints of clinical trial populations—to inform clinical care, risk stratification and value-based risk sharing arrangements. Our

71 primary hypothesis is that sustained GLP-1RA use reduces the cumulative incidence
72 of ESRD, ESLD and MACE and delays their onset.

73 **Methods**

74 **Ethics statement**

75 This study was deemed exempt by the Sterling Institutional Review Board
76 (protocol #12167) with waiver of informed consent and followed the Strengthening
77 the Reporting of Observational Studies in Epidemiology (STROBE) reporting
78 guidelines.

79 **Setting and Data Sources**

80 We used the Blue Cross Blue Shield (BCBS) Association's National Data
81 Warehouse,[1] containing medical claims data from participating BCBS plans. Adults
82 aged 18-64 (January 1, 2016-August 31, 2024) residing in the United States with
83 commercial medical and pharmacy insurance were potentially eligible
84 (N=24,987,055; Table S1).

85 **Cohort Construction**

86 Treated members had ≥1 pharmacy claims for a GLP-1RA product (tirzepatide,
87 albiglutide, semaglutide, liraglutide, lixisenatide, dulaglutide, or exenatide) between
88 January 1, 2017 and February 29, 2024, with ≥12 months baseline continuous medical
89 and pharmacy enrollment and ≥6 months follow-up after the initial prescription fill
90 (index date; N=1,725,097).

91 Control members had no prescription fills for any GLP-1RA products between
92 January 1, 2017 and August 31, 2024 and ≥18 months of continuous medical and

[1] The National Data Warehouse (NDW) is a national data asset managed by BCBSA that houses BCBS Plan submitted data (e.g., medical claims, membership data) to support healthcare operations, program capabilities, and analytics.

93 pharmacy enrollment (N=23,261,958). Controls were randomly assigned a proxy
94 exposure or pseudo-index date within quarterly periods from January 1, 2017 through
95 February 29, 2024.[18]
96 Members in both cohorts were classified as having a condition if they had ≥1 inpatient
97 facility claims or ≥2 professional claims on separate days (excluding ambulance,
98 DME, laboratory, and imaging claims) with relevant ICD-10 diagnoses in their
99 baseline year. Both cohorts excluded members with GLP-1RA contraindications,
100 high-cost conditions (e.g. cancers except squamous and basal cell carcinoma,
101 mechanical ventilation > 96 hours), conditions limiting long-term treatment (e.g.
102 dementia, end of life conditions), or bariatric procedures, yielding 936,777 treated
103 members and 18,281,409 eligible controls (Table S1).
104 **Matching**
105 Treated members were exact-matched to controls on gender, age group, index
106 or pseudo-index year-quarter, and baseline diabetes and weight status. Propensity
107 score matching (caliper=0.05 standard deviations of the logit) was then performed on
108 baseline comorbidities (anxiety, depression, asthma, COPD, obstructive sleep apnea,
109 hypertension, dyslipidemia, cerebrovascular disease, chronic kidney disease, coronary
110 artery disease, heart failure (HF), early-stage liver disease, late-stage liver disease,
111 alcohol or opiate use disorder, pancreatitis, psoriatic and rheumatic disease, and
112 weight-bearing joint pain), race and ethnicity (RAND Bayesian Improved First Name
113 Surname Geocoding imputation), and healthcare utilization (diabetes medications,
114 cardiovascular medications, non-bariatric inpatient stays, and number of unique drug
115 classes filled).[19] A 1:1 match ratio without replacement yielded 742,824 matched
116 pairs—413,404 with diabetes and 329,420 without diabetes. Additional information

117 on the definition of baseline matching conditions appears in the Methodology
118 Supplement.

119 **Clinical Outcomes**

120 Clinical outcomes were identified using a combination of International
121 Classification of Diseases, 10th Revision diagnosis (ICD-10-CM) codes, Current
122 Procedural Terminology (CPT) and Healthcare Common Procedure Coding System
123 (HCPCS) codes, Diagnosis-Related Groups (DRGs), and revenue center codes.
124 Claims for diagnostic testing, imaging, durable medical equipment, or ambulance
125 transport were excluded. The outcome onset date was defined as the earliest claim
126 date meeting the outcome criteria within the 6-year follow-up period. Outcomes
127 required ≥1 inpatient claim or ≥2 non-inpatient claims within 365 days except as
128 noted for kidney dialysis and specified MACE components.

129 ESRD was identified by the earliest of kidney dialysis lasting ≥28 days or a
130 kidney transplant.[20,21] ESLD was identified by the earliest of hepatic failure, liver
131 transplant, or hepatocellular carcinoma. MACE comprised: (1) ≥1 inpatient claim for
132 HF, acute coronary syndrome (ACS) / unstable angina (UA), acute MI, stroke, or
133 urgent/emergent coronary revascularization; or (2) ≥2 non-inpatient claims for acute
134 MI or stroke.[22]

135 Outcomes were censored at the earliest of the end of follow-up, the first event,
136 or 6 years post-index. To avoid misclassification of prevalent conditions, members
137 with evidence of each outcome during the 12-month baseline or within 30 days after
138 the index or pseudo-index date were excluded from analyses of that outcome.

Follow-Up

Members were followed until disenrollment from medical or pharmacy benefits, the end of the study period (31 August 2024), or 6 years post-index or pseudo-index date. Median follow-up time was 20 months for treated members and 19 months for controls. Persistence of GLP-1RA treatment was assessed by aggregating all GLP-1RA treatment periods for each member, allowing gaps of up to 90 days; gaps exceeding 90 days indicated discontinuation. Persistence patterns differed by diabetes status: 52.4% of those with diabetes and 66.5% of those without diabetes persisted for <1 year (short-term users), 29.1% of those with diabetes and 27.5% of those without diabetes persisted for 1 to <2 years (moderate-term users), and 18.5% of those with diabetes and 6.0% of those without diabetes persisted for ≥2 years (long-term users; Table S3).

Statistical Analysis

Analyses were conducted with R Studio Version 2024.04.2 using the matchit and survival packages. Baseline characteristics were summarized using means and 95% confidence intervals for continuous variables, and frequency distributions for categorical variables.

Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals over the 6-year follow-up period, stratified by diabetes status. Kaplan-Meier survival models assessed time-to-event outcomes, with cumulative incidence (events per 100 person-months) estimates calculated as 1 minus the Kaplan-Meier survival estimator, assuming no competing risks. Log-rank tests compared survival differences between groups over the 6-year follow-up period. Proportional hazards assumptions for the Cox models were verified using scaled Schoenfeld residuals, where global and cohort-specific tests with non-significant p-values

confirmed proportionality. Bonferroni adjustment addressed multiple comparisons for each outcome, where unadjusted p-values were compared to an adjusted threshold of 0.05 divided by the number of comparisons being made.

Results

Baseline characteristics

Matched treated and control members were well-balanced on demographic and clinical characteristics. In members with diabetes, the mean age was 52.4 years in the treated group and 52.5 years in the control group; 51.0% of each group were male (Table 1). Most had type 2 diabetes without complications (63.7%), and the most common comorbidities were hypertension (61.8% of treated vs 63.6% of controls) and dyslipidemia (72.0% of treated vs 73.4% of controls). Follow-up time varied by GLP-1RA treatment persistence. At least 3 years of follow-up were available for 34,188 short-term treated (<1 year), 11,280 medium-term treated (1 to <2 years), 41,284 long-term treated (≥2 years), and 72,805 matched controls (Table S4).

Treated and control members without diabetes had a mean age of 46.7 years, and 75.7% were female, 45.1% had a diagnosis of obesity or overweight. Hypertension and dyslipidemia were the most common comorbidities, with similar prevalence between treated and control groups. At least 3 years of follow-up were available for 20,589 short-term treated, 5,252 moderate-term treated, 7,453 long-term treated, and 31,547 matched controls.

End-Stage Renal Disease

Treated members with diabetes had a 45% lower risk of ESRD ($p<0.001$) compared to controls (Figure 1). The magnitude of the effect was similar for dialysis and kidney transplant, the two components of ESRD (Figure 1; Table 2). We found a strong 'persistence response curve' for ESRD in members with diabetes: those treated

189 for ≥2 years had a 73% lower risk (p<0.001), members treated for 1-<2 years had a
190 55% lower risk (p<0.001) than controls, while members treated for <1 year had no
191 significant risk reduction (Figure 2; Table 2). GLP-1RA treatment delayed the onset
192 of ESRD: at 3 years, 0.42% of controls developed ESRD, an incidence rate delayed
193 by 1.2 years in members with any GLP-1RA treatment and 2.7 years in members
194 treated for ≥2 years.

195 In members without diabetes, there was a 34% reduction in ESRD risk
196 (p=0.02) (Figure 1). Few members without diabetes had 6 years of follow-up, and
197 cumulative incidence of ESRD was low among treated and controls (0.12% versus
198 0.11%; Table 2). We found no relationship between treatment persistence and risk of
199 ESRD in members without diabetes (Figure 2; Table 2).

200 *End-Stage Liver Disease*

201 GLP-1RA treatment was associated with lower ESLD risk in members with
202 and without diabetes (Figure 1). For members with diabetes, any GLP-1RA treatment
203 was associated with a 34% lower risk (p<0.001) of ESLD (Figure 1; Table 3). For
204 members with diabetes, the magnitude of the effect was similar for all three
205 components of the composite measure (Figure 1). In treated members without
206 diabetes there was a 24% reduction in ESLD, although the absolute differences in
207 ESLD incident rates were small, and only two of the component measures (liver
208 transplant, hepatic failure) were significantly lower in treated members (Figure 1;
209 Table 3).

210 The relationship between GLP-1RA persistence and reduced ESLD differed
211 by diabetes status. For members with diabetes, a sustained effect was found only in
212 members treated for ≥2 years (Figure 3; Table 3). For members without diabetes, we
213 found a sustained reduction in ESLD only in those treated between 1-2 years (Figure

214 3; Table 3). GLP-1RA treatment delayed the onset of ESLD among members with
215 diabetes: at 3 years, 0.48% of controls had developed ESLD, a threshold not reached
216 by members with any GLP-1RA treatment until an additional 8 months had elapsed.
217 The delay was significantly more pronounced with longer GLP-1RA treatment, with
218 long-term treated individuals taking an additional 2.3 years to reach this threshold.

219 *Major Adverse Cardiac Events*

220 GLP-1RA treatment was associated with a lower risk of MACE in members
221 with and without diabetes: relative risk was reduced by 10% and 8%, respectively
222 (Figure 1). Among members with diabetes, risks of three of the five component events
223 were reduced, the largest impact was on stroke and hospital admission for HF. Among
224 members without diabetes, stroke risk was reduced by 16%, the largest component-
225 specific effect ($p<0.001$).

226 MACE had the highest cumulative incidence of the three clinical outcome
227 measures. By 6 years, 6.7% of untreated members with diabetes and 2.2% of
228 members without diabetes had experienced a MACE (Figure 4; Table 4). Absolute
229 risk differences favored GLP-1RA therapy; detailed estimates are provided in Table 4.

230 Among members with diabetes, treatment for ≥2 years was associated with a
231 1.5 percentage-point absolute reduction in 6-year MACE incidence–the largest
232 absolute reduction observed across outcomes–and with delayed MACE onset. The
233 controls' 3-year cumulative MACE incidence of 3.3% was reached approximately 3
234 months later among those with any GLP-1RA exposure and 1.0 year later among
235 those treated for ≥2 years. Among members without diabetes, MACE rates did not
236 differ significantly after the 2nd year of follow-up regardless of treatment persistence.

237 **Discussion**

238 Our study is one of the largest published on the clinical impact of GLP-1RA
239 use in actual practice. For members with diabetes, we find treatment with GLP-1RAs
240 substantially decreases the risk of developing ESRD, ESLD or experiencing a MACE
241 event. Members with diabetes are at much greater risk of developing ESRD, ESLD or
242 experiencing a MACE event at baseline and this is reflected in the higher absolute
243 reduction of these outcomes compared to members without diabetes. For members
244 without diabetes, while the effects are more modest, we still find that treated members
245 have lower rates of all three major outcomes. Our other major finding is that
246 members with longer persistence are more likely to benefit. These results extend
247 randomized-trial findings to unselected, working-age adults and quantify—for the
248 first time in routine practice—the multi-year deferral of kidney, liver, and composite
249 cardiovascular events.

250 Cardiovascular outcomes trials (including LEADER, SUSTAIN-6, and
251 REWIND) have demonstrated that GLP-1RAs reduce the incidence of MACE and
252 slow the progression of CKD. However, these trials enrolled highly selected patient
253 populations and did not measure hard ESLD end points or time-to-event delays.[11-13]
254 The 45% relative reduction in ESRD observed in our study aligns with the 45%
255 decline in the renal composite reported for dulaglutide in REWIND, our
256 accompanying finding of a 2.7-year delay in ESRD represents a new clinically
257 meaningful finding. At the population level, treating 250 treatment-adherent patients
258 for a year prevents one renal-failure case—an effectiveness comparable to statins for
259 secondary prevention of MI.

260 Real-world data on ESLD have been sparse and heterogeneous; the present
261 study demonstrates a 34% reduction in hazard and a 2.3-year delay in progression to

262 hepatic failure or transplant.[23] The attenuation of acute MI risk—non-significant
263 overall but reduced by 34% with long-term GLP-1RA exposure—mirrors trial-based
264 observations that coronary benefit may accrue more slowly than cerebrovascular or
265 heart-failure benefit, potentially reflecting differing pathophysiologic mechanisms and
266 persistence of exposure requirements.

267 Longer follow-up studies are recommended to evaluate the impact of GLP-
268 1RAs on people without diabetes. In this study, the follow-up time and smaller
269 absolute event rates in members without diabetes yielded wide confidence intervals
270 around HR estimates. For approximately every 235 patients with diabetes who stay
271 on a GLP-1RA for ≥12 months, one case of end-stage renal disease is averted within 6
272 years, and for liver failure the figure is approximately 270. Combined with the 2.7
273 year delay in dialysis and the 2.3 year delay in transplant-eligible ESLD, GLP1-RA
274 treatment could result in significant reductions in medical costs for these rare but
275 serious outcomes.[24,25]

276 This study has several limitations. Semaglutide was approved for diabetes in
277 2017 and in 2021 for obesity. Consequently, the number of treated individuals
278 without diabetes available for analysis was lower than those with diabetes. However,
279 this is still one of the largest studies to date of the impact of GLP-1RAs on people
280 without diabetes. While diabetes is consistently coded in claims data, obesity is not.[26]
281 Our decision to consider all members without diabetes as a single cohort should be
282 evaluated through comparing clinical data, such as electronic medical records, with
283 claims data. Finally, the study was limited to members receiving GLP-1RAs via
284 insurance benefits. Untreated members could have accessed GLP-1RAs via alternate
285 mechanisms such as compounding pharmacies. Any misclassification would
286 attenuate the observed differences between treated and untreated members.

We found that in members with diabetes persistent GLP-1RA therapy was associated with a reduced incidence and delayed onset of kidney and liver failure, as well as reduced rates of stroke and HF hospitalization. These findings provide real-world evidence of both clinical benefit and potential economic value among select patient population within a commercially insured cohort. Our study supports guideline recommendations to prioritize GLP-1RAs for high-risk patients and underscore the importance of adherence programs capable of supporting patients to persist with therapy for ≥1 year.

Acknowledgements

Author Contributions: AM and CM had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: HC, DW, AM, CM
Acquisition, analysis, or interpretation of data: HC, AM, CM, DW
Drafting of the manuscript: HC, AM, CM, LAT, ST
Critical review of the manuscript for important intellectual content: HC, RH, JK, VV, SH, LAT, ST
Statistical analysis: AM, CM
Obtained funding: HC
Administrative, technical, or material support: RH, JK, VV, SH, LAT
Supervision: HC, DW
Conflict of Interest Disclosures: No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript. Dr. Hashmi reported receiving stock and options from Elevance Health. Dr. Wennberg serves as a consultant to Blue Health Intelligence. No disclosures for other authors.
Funding/Support: This study was funded by the Blue Cross Blue Shield Association.
Role of the Funder/Sponsor: The funder had a role in the collection of the data. The funder had no role in the management of the data, conduct or design of the study, analysis, or interpretation of the data. The funder had no role in the preparation of the manuscript. The funder had a role in the review and approval of the manuscript. The authors jointly agreed to submit the manuscript for publication.

AI Used in Manuscript Preparation: The drafting and refinement of this manuscript were supported by OpenAI's ChatGPT, which assisted in enhancing the language and clarity of the text.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding entity.

Data Sharing Statement: Data will not be shared.

Additional Contributions: The authors acknowledge Bob Darin (concept, design, review), Bolatito Adepoju (editing) and Thomas Parakilatu, Neha Jajodia, and Jen Zhong (data management) for their valuable contributions to this project.

Disclosures: © 2025 Blue Cross Blue Shield Association. All Rights Reserved. Blue Health Intelligence, Blue Cross Blue Shield of Massachusetts, and Hawaii Medical Service Association, are all licensees of the Blue Cross Blue Shield Association, an association of independent, locally operated Blue Cross and Blue Shield companies. The National Data Warehouse (NDW) is a national data asset managed by BCBSA that houses BCBS Plan submitted data (e.g., medical claims, membership data) to support healthcare operations, program capabilities, and analytics. Blue Health Intelligence (BHI) empowers healthcare organizations to improve outcomes, reduce costs, and drive innovation through data and analytics. Blue Health Intelligence (BHI) is a trade name of Health Intelligence Company LLC, an independent licensee of the Blue Cross Blue Shield Association.

References

1. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010;3:285-95. DOI: 10.2147/DMSOTT.S7384.
2. Adult Obesity Facts. Centers for Disease Control and Prevention. (https://www.cdc.gov/obesity/php/data-research/adult-obesity-facts.html).
3. Association AD. Statistics About Diabetes. November 2, 2023 (https://diabetes.org/about-diabetes/statistics/about-diabetes).

348 4. Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, et al. Body-mass
349 index and all-cause mortality: individual-participant-data meta-analysis of 239
350 prospective studies in four continents. Lancet 2016;388(10046):776-86. DOI:
351 10.1016/S0140-6736(16)30175-1.
352 5. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass
353 index with health care expenditures in the United States by age and sex. PLoS
354 One 2021;16(3):e0247307. DOI: 10.1371/journal.pone.0247307.
355 6. Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ. Indirect
356 costs of obesity: a review of the current literature. Obes Rev 2008;9(5):489-
357 500. DOI: 10.1111/j.1467-789X.2008.00472.x.
358 7. Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ.
359 Cardiovascular safety of albiglutide in the Harmony programme: a meta-
360 analysis. Lancet Diabetes Endocrinol 2015;3(9):697-703. DOI:
361 10.1016/S2213-8587(15)00233-8.
362 8. FDA. Declaratory Order: Resolution of Shortages of Semaglutide Injection
363 Products (Ozempic and Wegovy).
364 (https://www.fda.gov/media/185526/download).
365 9. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of
366 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-
367 22. (In eng). DOI: 10.1056/NEJMoa1411892.
368 10. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.
369 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide
370 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
371 Diabetologia 1993;36(8):741-4. (In eng). DOI: 10.1007/bf00401145.

372 11. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and
373 cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind,
374 randomised placebo-controlled trial. Lancet 2019;394(10193):121-130. DOI:
375 10.1016/S0140-6736(19)31149-3.
376 12. Gilbert MP, Skelly J, Hernandez AF, et al. Effect of albiglutide on
377 cardiovascular outcomes in older adults: A post hoc analysis of a randomized
378 controlled trial. Diabetes Obes Metab 2024;26(5):1714-1722. DOI:
379 10.1111/dom.15479.
380 13. Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and
381 cardiovascular outcomes with once-weekly subcutaneous semaglutide in the
382 treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes
383 Metab 2019;45(5):409-418. DOI: 10.1016/j.diabet.2018.12.001.
384 14. Meurot C, Jacques C, Martin C, et al. Targeting the GLP-1/GLP-1R axis to
385 treat osteoarthritis: A new opportunity? J Orthop Translat 2022;32:121-129.
386 DOI: 10.1016/j.jot.2022.02.001.
387 15. Krajnc N, Itariu B, Macher S, et al. Treatment with GLP-1 receptor agonists is
388 associated with significant weight loss and favorable headache outcomes in
389 idiopathic intracranial hypertension. J Headache Pain 2023;24(1):89. DOI:
390 10.1186/s10194-023-01631-z.
391 16. Foley HE, Knight JC, Ploughman M, Asghari S, Audas R. Identifying cases of
392 chronic pain using health administrative data: A validation study. Can J Pain
393 2020;4(1):252-267. DOI: 10.1080/24740527.2020.1820857.
394 17. Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based
395 therapies and disease course of inflammatory bowel disease.
396 EClinicalMedicine 2021;37:100979. DOI: 10.1016/j.eclinm.2021.100979.

397 18. Harvey R, Drzayich Jankus D, Mosley D. Random assignment of proxy event
398 dates to unexposed individuals in observational studies: An automated
399 technique using SAS®. MWSUG 2012. Minneapolis, MN2012.
400 19. RAND Bayesian Improved Surname Geocoding.
401 (https://www.rand.org/health-care/tools-methods/bisg.html).
402 20. Wysham CH, Gauthier-Loiselle M, Bailey RA, et al. Development of risk
403 models for major adverse chronic renal outcomes among patients with type 2
404 diabetes mellitus using insurance claims: a retrospective observational study.
405 Current Medical Research and Opinion 2020;36(2):219-227. DOI:
406 10.1080/03007995.2019.1682981.
407 21. Pan H-C, Chen J-Y, Chen H-Y, et al. GLP-1 receptor agonists' impact on
408 cardio-renal outcomes and mortality in T2D with acute kidney disease. Nature
409 Communications 2024;15(1):5912. DOI: 10.1038/s41467-024-50199-y.
410 22. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse
411 cardiovascular event definitions used in observational analysis of
412 administrative databases: a systematic review. BMC Med Res Methodol
413 2021;21(1):241. DOI: 10.1186/s12874-021-01440-5.
414 23. Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagström H. Glucagon-
415 like peptide-1 receptor agonists and risk of major adverse liver outcomes in
416 patients with chronic liver disease and type 2 diabetes. Gut 2024;73(5):835-
417 843. (In eng). DOI: 10.1136/gutjnl-2023-330962.
418 24. USRDS. Healthcare Expenditures for Persons with ESRD. End-Stage Renal
419 Disease: Chapter 9. 2023. (https://usrds-adr.niddk.nih.gov/2023/end-stage-
420 renal-disease/9-healthcare-expenditures-for-persons-with-esrd).

421 25. Ortner NH, Hanna. 2025 U.S. organ and tissue transplants: Estimated costs
422 and utilization, emerging issues, and solutions. 2025.
423 (https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-
424 costs-utilization).
425 26. Ammann EM, Kalsekar I, Yoo A, Johnston SS. Validation of body mass index
426 (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes
427 recorded in US claims data. Pharmacoepidemiol Drug Saf 2018;27(10):1092-
428 1100. (In eng). DOI: 10.1002/pds.4617.
429

430 **Table 1: Characteristics of Matched GLP-1RA Treated and Control Cohorts**

Characteristic considered in the matching algorithm	Members with Diabetes			Members without Diabetes		
	Treated	Controls	SMD	Treated	Controls	SMD
	N = 413,404	N = 413,404		N = 329,420	N = 329,420	
Age at Index (Years), mean (SD)	52.4 (8.8)	52.5 (8.9)	0.01	46.7 (10.2)	46.7 (10.3)	0.01
Gender (% Female)	49.0%	49.0%	0	75.7%	75.7%	0
Race/Ethnicity						
White	63.5%	61.1%	0.05	70.5%	70.9%	0.01
Black	8.3%	8.8%	0.02	7.2%	7.2%	0
Hispanic	10.7%	11.7%	0.03	7.1%	7.1%	0
Other	4.6%	5.1%	0.02	2.9%	2.5%	0.02
Unknown	12.8%	13.3%	0.01	12.3%	12.3%	0
Type 1 Diabetes	2.0%	2.0%	0	0.0%	0.0%	0
Type 2 Diabetes with complications	34.3%	34.3%	0	0.0%	0.0%	0
Type 2 Diabetes without complications	63.7%	63.7%	0	0.0%	0.0%	0
Obesity	35.7%	35.7%	0	45.1%	45.1%	0
Liver Disease	4.2%	4.0%	0.01	2.7%	2.2%	0.01
Hypertension	61.8%	63.6%	0.04	35.4%	35.9%	0.01
Anxiety	11.7%	11.9%	0.01	20.1%	20.2%	0.00
Depression	9.4%	9.4%	0.00	14.0%	13.8%	0.01
Heart Failure	2.1%	2.1%	0.00	0.6%	0.3%	0.03
Coronary Artery Disease	6.9%	6.6%	0.01	2.1%	1.9%	0.01
Chronic Kidney Disease	4.2%	4.2%	0	0.9%	0.7%	0.02
Obstructive Sleep Apnea	11.0%	10.3%	0.02	9.7%	9.1%	0.02
Prior Treatment						
Insulin	13.6%	12.9%	0.02	0.0%	0.0%	0.00
SGLT2 Inhibitors	18.6%	16.2%	0.06	0.0%	0.0%	0.00
Sulfonylureas[a]	21.9%	21.3%	0.01	0.0%	0.0%	0.00
DPP-4 Inhibitors	10.5%	9.9%	0.02	0.0%	0.0%	0.00
Biguanides	72.4%	73.8%	0.03	2.3%	1.3%	0.08
Number of non-bariatric inpatient stays						
0	95.0%	95.2%	0.01	97.6%	97.8%	0.01
1	4.2%	3.9%	0.01	2.0%	1.9%	0.01
2+	0.9%	0.9%	0	0.3%	0.3%	0.01
Number of other prescription classes used at baseline						
0	5.2%	4.7%	0.02	4.5%	4.6%	0
1 to 3	30.4%	29.8%	0.01	25.0%	24.9%	0
4 to 6	29.3%	29.7%	0.01	28.0%	28.1%	0
7 to 9	17.9%	18.3%	0.01	20.1%	20.2%	0
10+	17.1%	17.5%	0.01	22.4%	22.3%	0

431 [a] The sulfonylureas category also includes meglitinide analogues and thiazolidinediones.

Table 2: 6-Year Cumulative Incidence and Hazard of End-Stage Renal Disease

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
End-Stage Renal Disease	**Controls**	0.94±0.10					0.11±0.05				
	Treated: Overall	**0.67±0.08**	**<0.001**	**0.55**	**0.49-0.61**	**<0.001**	0.12±0.06	0.807	0.66	0.46-0.94	0.021
	Treated: <1 year	0.92±0.13	0.809	0.82	0.70-0.96	0.012	0.12±0.08	0.831	0.62	0.4-0.96	0.031
	Treated: 1-<2 years	**0.57±0.18**	**<0.001**	**0.45**	**0.35-0.57**	**<0.001**	0.23±0.24	0.345	0.82	0.41-1.67	0.591
	Treated: >= 2 years	**0.46±0.11**	**<0.001**	**0.27**	**0.21-0.35**	**<0.001**	0.05±0.04	0.050	0.57	0.17-1.95	0.372
Kidney Transplant	**Controls**	0.12±0.03					0.03±0.02				
	Treated: Overall	0.11±0.03	0.660	**0.60**	**0.45-0.81**	**0.001**	0.03±0.02	1.000	0.60	0.35-1.03	0.064
	Treated: <1 year	0.13±0.05	0.716	0.65	0.43-0.97	0.036	0.03±0.03	1.000	0.46	0.22-0.94	0.032
	Treated: 1-<2 years	0.11±0.09	0.838	0.65	0.37-1.13	0.127	0.03±0.03	1.000	1.20	0.37-3.93	0.763
	Treated: >= 2 years	0.09±0.06	0.366	0.47	0.25-0.88	0.019	0.03±0.02	1.000	0.67	0.19-2.36	0.530
Dialysis	**Controls**	0.89±0.10					0.08±0.04				
	Treated: Overall	**0.63±0.07**	**<0.001**	**0.54**	**0.48-0.61**	**<0.001**	0.10±0.06	0.606	0.71	0.45-1.12	0.140
	Treated: <1 year	0.86±0.13	0.710	0.85	0.72-1.0	0.046	0.09±0.07	0.820	0.73	0.42-1.27	0.269
	Treated: 1-<2 years	0.57±0.19	0.003	**0.42**	**0.32-0.55**	**<0.001**	0.21±0.24	0.304	0.77	0.34-1.75	0.533
	Treated: >= 2 years	**0.44±0.11**	**<0.001**	**0.25**	**0.19-0.33**	**<0.001**	0.02±0.03	0.025	-	-	-

[a] Raw p-values for GLP-1 users overall were compared to a threshold of α=0.05. P-values by degree of GLP-1 persistence were compared to a Bonferroni-adjusted threshold of α=0.017 (0.05/3).

432

433 **Table 3: 6-Year Cumulative Incidence and Hazard of End-Stage Liver Disease**

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
End-Stage Liver Disease	**Controls**	1.08±0.11					0.26±0.07				
	Treated: Overall	**0.86±0.09**	**0.002**	**0.66**	**0.60-0.73**	**<0.001**	0.27±0.08	0.85	0.76	0.62-0.93	0.008
	Treated: <1 year	0.98±0.13	0.257	0.96	0.84-1.11	0.594	0.30±0.11	0.54	0.95	0.74-1.22	0.705
	Treated: 1-<2 years	1.01±0.28	0.649	**0.57**	**0.47-0.70**	**<0.001**	0.15±0.11	0.11	**0.43**	**0.28-0.66**	**<0.001**
	Treated: >= 2 years	**0.67±0.13**	**<0.001**	**0.37**	**0.30-0.45**	**<0.001**	0.26±0.15	1.00	0.68	0.35-1.31	0.253
Liver Cancer	**Controls**	0.17±0.04					0.05±0.05				
	Treated: Overall	0.20±0.04	0.306	0.71	0.56-0.89	0.003	0.02±0.02	0.23	0.93	0.54-1.58	0.786
	Treated: <1 year	0.24±0.08	0.103	1.17	0.84-1.64	0.348	0.03±0.03	0.45	1.64	0.85-3.19	0.143
	Treated: 1-<2 years	0.23±0.13	0.384	0.65	0.41-1.03	0.069	0.00±0.00	0.03	0.25	0.05-1.18	0.080
	Treated: >= 2 years	0.14±0.06	0.392	**0.30**	**0.18-0.50**	**<0.001**	0.01±0.02	0.11	0.17	0.02-1.38	0.097
Liver Transplant	**Controls**	0.09±0.04					0.02±0.03				
	Treated: Overall	0.06±0.02	0.176	0.61	0.41-0.89	0.011	0.02±0.01	1.00	0.43	0.21-0.91	0.028
	Treated: <1 year	0.07±0.03	0.434	0.89	0.51-1.54	0.675	0.02±0.02	1.00	0.50	0.20-1.24	0.134
	Treated: 1-<2 years	0.12±0.11	0.603	0.47	0.21-1.05	0.065	0.00±0.00	0.12	0.25	0.05-1.18	0.080
	Treated: >= 2 years	0.05±0.03	0.089	0.39	0.18-0.85	0.017	0.02±0.03	1.00	1.00	0.06-15.99	1.000
Hepatic Failure	**Controls**	0.93±0.10					0.24±0.07				
	Treated: Overall	0.73±0.08	**0.003**	**0.66**	**0.60-0.74**	**<0.001**	0.25±0.08	0.85	0.76	0.61-0.94	0.012
	Treated: <1 year	0.84±0.12	0.272	0.97	0.84-1.13	0.702	0.27±0.10	0.64	0.92	0.71-1.20	0.541
	Treated: 1-<2 years	0.83±0.25	0.475	**0.57**	**0.46-0.71**	**<0.001**	0.14±0.11	0.14	**0.42**	**0.27-0.68**	**<0.001**
	Treated: >= 2 years	0.59±0.12	**<0.001**	**0.36**	**0.28-0.45**	**<0.001**	0.25±0.15	0.90	0.81	0.39-1.69	0.578

434 [a] Raw p-values for GLP-1 users overall were compared to a threshold of α=0.05. P-values by degree of GLP-1 persistence were compared to a
435 Bonferroni-adjusted threshold of α=0.017 (0.05/3).

Table 4: 6-Year Cumulative Incidence and Hazard of Major Adverse Cardiac Events

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
MACE	**Controls**	6.68±0.25					2.24±0.24				
	Treated: Overall	6.46±0.23	0.204	**0.90**	**0.86-0.93**	**<0.001**	2.49±0.25	0.152	0.92	0.86-0.99	0.019
	Treated: <1 year	**7.67±0.38**	**<0.001**	**1.17**	**1.12-1.23**	**<0.001**	2.57±0.30	0.094	1.04	0.95-1.14	0.390
	Treated: 1-<2 years	7.10±0.70	0.269	**0.77**	**0.71-0.82**	**<0.001**	2.40±0.58	0.615	**0.72**	**0.62-0.82**	**<0.001**
	Treated: >= 2 years	**5.09±0.30**	**<0.001**	**0.63**	**0.59-0.68**	**<0.001**	2.33±0.61	0.788	0.81	0.65-1.02	0.070
Acute MI	**Controls**	3.30±0.19					1.10±0.17				
	Treated: Overall	3.14±0.16	0.203	0.94	0.89-0.99	0.020	1.14±0.16	0.741	0.89	0.80-0.99	0.037
	Treated: <1 year	**3.73±0.27**	**0.010**	**1.29**	**1.19-1.39**	**<0.001**	1.23±0.21	0.352	0.96	0.84-1.09	0.503
	Treated: 1-<2 years	3.69±0.55	0.190	**0.77**	**0.70-0.86**	**<0.001**	0.96±0.37	0.505	0.77	0.63-0.95	0.013
	Treated: >= 2 years	**2.43±0.20**	**<0.001**	**0.66**	**0.60-0.73**	**<0.001**	0.96±0.33	0.459	0.86	0.61-1.21	0.385
Acute Coronary Syndrome	**Controls**	0.48±0.06					0.11±0.05				
	Treated: Overall	**0.60±0.07**	**0.011**	1.08	0.96-1.22	0.181	**0.20±0.07**	**0.037**	1.36	1.01-1.82	0.040
	Treated: <1 year	**0.71±0.12**	**0.001**	1.31	1.11-1.56	**0.002**	0.16±0.07	0.255	1.38	0.95-2.01	0.090
	Treated: 1-<2 years	0.59±0.21	0.326	0.85	0.67-1.09	0.196	0.18±0.14	0.349	1.18	0.67-2.09	0.564
	Treated: >= 2 years	0.52±0.09	0.472	0.96	0.76-1.21	0.727	0.33±0.27	0.113	1.67	0.73-3.81	0.226

439 **Table 4. Continued**

Outcome	Degree of GLP-1 Persistence	Members with Diabetes					Members without Diabetes				
		Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]	Cumulative Incidence (%, ± 95% CI)	Cumulative Incidence P-Value	HR	95% CI	Cox P-Value[a]
Heart Failure	**Controls**	1.46±0.13					0.24±0.09				
	Treated: Overall	**1.15±0.10**	**<0.001**	**0.76**	**0.70-0.83**	**<0.001**	0.28±0.08	0.518	1.19	0.95-1.49	0.134
	Treated: <1 year	1.54±0.17	0.468	1.19	1.05-1.33	0.004	0.32±0.11	0.271	**1.64**	**1.22-2.20**	**0.001**
	Treated: 1-<2 years	1.27±0.27	0.214	**0.59**	**0.50-0.71**	**<0.001**	0.27±0.21	0.800	0.82	0.51-1.31	0.407
	Treated: >= 2 years	**0.72±0.13**	**<0.001**	**0.37**	**0.30-0.44**	**<0.001**	0.14±0.09	0.117	0.50	0.26-0.97	0.041
Stroke	**Controls**	2.48±0.15					0.91±0.15				
	Treated: Overall	2.43±0.15	0.645	**0.82**	**0.77-0.87**	**<0.001**	1.00±0.16	0.417	0.84	0.75-0.93	**0.001**
	Treated: <1 year	**2.92±0.25**	**0.004**	1.04	0.96-1.13	0.303	1.01±0.19	0.419	0.99	0.86-1.14	0.889
	Treated: 1-<2 years	2.52±0.43	0.863	**0.74**	**0.66-0.83**	**<0.001**	1.04±0.37	0.519	**0.60**	**0.49-0.75**	**<0.001**
	Treated: >= 2 years	**1.91±0.20**	**<0.001**	**0.58**	**0.51-0.65**	**<0.001**	0.97±0.45	0.804	0.68	0.48-0.98	0.039
Cardiac Revascularization	**Controls**	1.71±0.13					0.43±0.10				
	Treated: Overall	1.86±0.12	0.104	1.04	0.97-1.11	0.272	0.51±0.11	0.292	1.10	0.94-1.29	0.254
	Treated: <1 year	**2.10±0.20**	**0.001**	**1.35**	**1.22-1.49**	**<0.001**	0.50±0.12	0.393	1.14	0.94-1.40	0.186
	Treated: 1-<2 years	2.19±0.41	0.030	0.92	0.80-1.06	0.250	0.47±0.26	0.780	1.00	0.73-1.37	1.000
	Treated: >= 2 years	1.55±0.16	0.136	**0.75**	**0.65-0.85**	**<0.001**	0.63±0.31	0.234	1.06	0.65-1.74	0.803

440 [a] Raw p-values for GLP-1 users overall were compared to a threshold of α=0.05. P-values by degree of GLP-1 persistence were compared to a
441 Bonferroni-adjusted threshold of α=0.017 (0.05/3).

Fig 1. Hazard of Incident ESRD, ESLD, and MACE between GLP-1RA Treated and Controls, for Members with and without Diabetes.



Hazard ratios (HR) and p-values were generated by Cox proportional hazards models over the 6-year member follow-up period. Statistical significance was established using a threshold of $\alpha = 0.05$.

Fig 2. Cumulative Incidence of ESRD by 3 Levels of GLP-1RA Persistence and Untreated Controls, for Members with and without Diabetes.



Cumulative Incidence of ESRD - Members with Diabetes (% ± 95% confidence interval)

	1	2	3	4	5	6
Controls	0.11 ± 0.01	0.24 ± 0.02	0.42 ± 0.03	0.60 ± 0.05	0.78 ± 0.07	0.94 ± 0.10
Treated <1 yr	0.07 ± 0.01	0.18 ± 0.03	0.36 ± 0.05	0.55 ± 0.07	0.79 ± 0.11	0.92 ± 0.13
Treated 1-2 yrs	0.04 ± 0.01	0.10 ± 0.03	0.24 ± 0.07	0.38 ± 0.11	0.49 ± 0.15	0.57 ± 0.18
Treated >=2 yrs	0.03 ± 0.01	0.07 ± 0.02	0.11 ± 0.03	0.22 ± 0.05	0.33 ± 0.07	0.46 ± 0.11

Cumulative Incidence of ESRD - Members without Diabetes (% ± 95% confidence interval)

	1	2	3	4	5	6
Controls	0.02 ± 0.00	0.03 ± 0.01	0.05 ± 0.01	0.06 ± 0.02	0.11 ± 0.05	0.11 ± 0.05
Treated <1 yr	0.01 ± 0.00	0.02 ± 0.01	0.04 ± 0.02	0.07 ± 0.03	0.08 ± 0.04	0.12 ± 0.08
Treated 1-2 yrs	0.01 ± 0.00	0.02 ± 0.02	0.04 ± 0.03	0.07 ± 0.06	0.12 ± 0.11	0.23 ± 0.23
Treated >=2 yrs	0.02 ± 0.02	0.03 ± 0.02	0.05 ± 0.04	0.05 ± 0.04	0.05 ± 0.04	0.05 ± 0.04

P-values

	1	2	3	4	5	6
vs. ■	<0.001	<0.001	0.04	0.26	0.88	0.81
vs. ■	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
vs. ■	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

P-values

	1	2	3	4	5	6
vs. ■	0.002	0.07	0.42	0.63	0.35	0.83
vs. ■	0.003	0.30	0.53	0.77	0.87	0.35
vs. ■	1.00	1.00	1.00	0.65	0.05	0.05

Log-rank p-value on the graphs shows that the cumulative incidence of ESRD varies by degree of persistence in members with diabetes but not significantly in members without diabetes. Tables below graphs show corresponding cumulative incidence rates (%) and 95% confidence bounds at one year timepoints. In the bottom table, raw p-values of Wald z-test comparisons between each GLP-1RA persistence stratum to the control group should be compared to a Bonferroni-adjusted threshold of $\alpha = 0.016$ (0.05/3).

Fig 3. Cumulative Incidence of ESLD by 3 Levels of GLP-1RA Persistence and Untreated Controls, for Members with and without Diabetes.



Cumulative Incidence of ESLD - Members with Diabetes (% ± 95% confidence interval)

	1	2	3	4	5	6
Controls	0.13 ± 0.01	0.30 ± 0.02	0.48 ± 0.03	0.64 ± 0.05	0.85 ± 0.07	1.08 ± 0.11
Treated <1 yr	0.13 ± 0.02	0.27 ± 0.03	0.46 ± 0.05	0.67 ± 0.08	0.79 ± 0.10	0.98 ± 0.14
Treated 1-2 yrs	0.05 ± 0.01	0.22 ± 0.04	0.42 ± 0.08	0.60 ± 0.13	0.77 ± 0.18	1.01 ± 0.28
Treated >=2 yrs	0.04 ± 0.01	0.09 ± 0.02	0.23 ± 0.04	0.35 ± 0.06	0.44 ± 0.07	0.67 ± 0.13

P-values	1	2	3	4	5	6
vs.	1.00	0.11	0.52	0.52	0.42	0.26
vs.	<0.001	0.001	0.19	0.57	0.42	0.65
vs.	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

Cumulative Incidence of ESLD - Members without Diabetes (% ± 95% confidence interval)

	1	2	3	4	5	6
Controls	0.04 ± 0.01	0.10 ± 0.01	0.15 ± 0.02	0.18 ± 0.03	0.23 ± 0.05	0.26 ± 0.07
Treated <1 yr	0.04 ± 0.01	0.07 ± 0.01	0.13 ± 0.03	0.19 ± 0.05	0.24 ± 0.07	0.30 ± 0.11
Treated 1-2 yrs	0.02 ± 0.01	0.05 ± 0.02	0.08 ± 0.05	0.10 ± 0.07	0.15 ± 0.11	0.15 ± 0.11
Treated >=2 yrs	0.02 ± 0.02	0.04 ± 0.03	0.15 ± 0.07	0.15 ± 0.07	0.26 ± 0.15	0.26 ± 0.15

P-values	1	2	3	4	5	6
vs.	1.00	0.005	0.33	0.75	0.82	0.54
vs.	<0.001	<0.001	0.008	0.03	0.21	0.11
vs.	0.07	<0.001	1.00	0.42	0.71	1.00

Log-rank p-value on the graphs shows that the cumulative incidence of ESLD varies by degree of persistence in members with and without diabetes. Tables below graphs show corresponding cumulative incidence rates (%) and 95% confidence bounds at one year time timepoints. In the bottom table, raw p-values of Wald z-test comparisons between each GLP-1RA persistence stratum to the control group should be compared to a Bonferroni-adjusted threshold of $\alpha = 0.016$ (0.05/3).

Fig 4. Cumulative Incidence of MACE by 3 Levels of GLP-1RA Persistence and Controls, for Members with and without Diabetes.



Cumulative Incidence of MACE - Members with Diabetes (% ± 95% confidence interval)

	1	2	3	4	5	6
Controls	1.02 ± 0.03	2.15 ± 0.06	3.27 ± 0.09	4.38 ± 0.13	5.53 ± 0.18	6.68 ± 0.25
Treated <1 yr	1.13 ± 0.05	2.36 ± 0.09	3.69 ± 0.14	4.87 ± 0.19	6.23 ± 0.27	7.67 ± 0.38
Treated 1-2 yrs	0.74 ± 0.05	1.68 ± 0.10	3.02 ± 0.21	4.50 ± 0.34	5.51 ± 0.45	7.10 ± 0.70
Treated >=2 yrs	0.67 ± 0.06	1.43 ± 0.09	2.31 ± 0.12	3.27 ± 0.16	4.22 ± 0.22	5.09 ± 0.30

P-values	1	2	3	4	5	6
vs.	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
vs.	<0.001	<0.001	0.03	0.52	0.90	0.27
vs.	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

Cumulative Incidence of MACE - Members without Diabetes (% ± 95% confidence interval)

	1	2	3	4	5	6
Controls	0.34 ± 0.02	0.67 ± 0.04	1.00 ± 0.06	1.38 ± 0.10	1.76 ± 0.15	2.24 ± 0.24
Treated <1 yr	0.31 ± 0.02	0.68 ± 0.05	1.10 ± 0.09	1.51 ± 0.14	2.02 ± 0.21	2.57 ± 0.31
Treated 1-2 yrs	0.24 ± 0.03	0.54 ± 0.07	0.99 ± 0.16	1.39 ± 0.27	1.97 ± 0.44	2.40 ± 0.58
Treated >=2 yrs	0.22 ± 0.07	0.55 ± 0.11	0.91 ± 0.15	1.26 ± 0.23	1.67 ± 0.36	2.33 ± 0.61

P-values	1	2	3	4	5	6
vs.	0.07	0.75	0.08	0.14	0.06	0.09
vs.	<0.001	0.001	0.91	0.95	0.40	0.62
vs.	<0.001	0.04	0.28	0.34	0.61	0.79

Log-rank p-value on the graphs shows that the cumulative incidence of MACE varies by degree of persistence in members with and without diabetes. Tables directly below graphs show corresponding cumulative incidence rates (%) and 95% confidence bounds at one year time intervals. Raw p-values of Wald z-test comparisons between each GLP-1RA persistence stratum to the control group should be compared to a Bonferroni-adjusted threshold of $\alpha = 0.016$ (0.05/3).